Physician profile
Matthew Licause
NPI 1205890019
$2,122.23
in general payments reported to CMS, 2019-2025
24 companies · $29.92 in 2025
The $29.92 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,349 · 2020: $265 · 2021: $83.52 · 2023: $376 · 2024: $19.20 · 2025: $29.92.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $425.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $425.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $350.64 | 2019-2023 | |
| Novo Nordisk INC | $342.64 | 2019-2023 | Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $220.16 | 2019-2023 | Ofev, Jardiance |
| Astrazeneca Pharmaceuticals Lp | $172.83 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $151.69 | 2019-2020 | |
| Amgen INC. | $130.43 | 2019-2025 | Evenity, Prolia |
| Lilly USA, LLC | $128.71 | 2019-2023 | Mounjaro |
| Radius Health, INC. | $70.86 | 2019-2020 | |
| Amarin Pharma, INC. | $59.70 | 2019 | |
| Astellas Pharma US INC | $56.69 | 2019-2023 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $53.71 | 2019-2020 | |
| Allergan, INC. | $53.19 | 2019-2020 | |
| Abbott Laboratories | $52.87 | 2023-2025 | Freestyle Libre 3 |
| Exact Sciences Corporation | $42.33 | 2023 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $41.40 | 2019-2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $41.37 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $33.74 | 2023 | Camzyos |
| Teva Pharmaceuticals USA, INC. | $26.77 | 2020 | |
| Arbor Pharmaceuticals, INC. | $23.90 | 2019-2020 | |
| Abbvie INC. | $17.88 | 2023 | |
| Sanofi-Aventis U.S. LLC | $15.67 | 2020 | |
| Mayne Pharma Commercial LLC | $12.04 | 2023 | |
| Janssen Pharmaceuticals, INC | $11.51 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $11.50 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Licause listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.